Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL) effectively induce remission; however, disease recurrence remains a challenge. Due to the potential for antigen loss, antigen diminution, lineage switch or development of a secondary or treatment-related malignancy, t...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2020-11, Vol.8 (2), p.e001563
Main Authors: Mo, George, Wang, Hao-Wei, Talleur, Aimee C, Shahani, Shilpa A, Yates, Bonnie, Shalabi, Haneen, Douvas, Michael G, Calvo, Katherine R, Shern, Jack F, Chaganti, Sridhar, Patrick, Katharine, Song, Young, Fry, Terry J, Wu, Xiaolin, Triplett, Brandon M, Khan, Javed, Gardner, Rebecca A, Shah, Nirali N
Format: Article
Language:English
Subjects:
adoptive
Antigens
Biopsy
Bone marrow
Cancer
Case Report
chimeric antigen
Cloning
Cytogenetics
Flow cytometry
Immunotherapy
Leukemia
Lymphocytes
receptors
Remission (Medicine)
Sarcoma
Stem cell transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL) effectively induce remission; however, disease recurrence remains a challenge. Due to the potential for antigen loss, antigen diminution, lineage switch or development of a secondary or treatment-related malignancy, the phenotype and manifestation of subsequent leukemia may be elusive. We report on two patients with multiply relapsed/refractory B-ALL who, following chimeric antigen receptor T-cell therapy, developed myeloid malignancies. In the first case, a myeloid sarcoma developed in a patient with a history of myelodysplastic syndrome. In the second case, two distinct events occurred. The first event represented a donor-derived myelodysplastic syndrome with monosomy 7 in a patient with a prior hematopoietic stem cell transplantation. This patient went on to present with lineage switch of her original B-ALL to ambiguous lineage T/myeloid acute leukemia. With the rapidly evolving field of novel immunotherapeutic strategies, evaluation of relapse and/or subsequent neoplasms is becoming increasingly more complex. By virtue of these uniquely complex cases, we provide a framework for the evaluation of relapse or evolution of a subsequent malignancy following antigen-targeted immunotherapy.
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2020-001563